Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

May 22, 2018

Oncolytics Biotech® Has Applied to List its Common Shares on Nasdaq and Announces Share Consolidation

May 17, 2018

Oncolytics Biotech® Announces Collaboration Between Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study

May 16, 2018

Oncolytics Biotech® Announces Publication of REOLYSIN® Abstract for the ASCO 2018 Annual Meeting

May 11, 2018

Oncolytics Biotech® Reports 2018 First Quarter Results

May 10, 2018

Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer

May 4, 2018

Oncolytics Biotech® Announces Voting Results from its Annual General Meeting of Shareholders

April 26, 2018

Oncolytics Biotech(R) Announces Details of 2018 Annual General Meeting of Shareholders

April 18, 2018

Oncolytics Biotech(R) Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018

April 17, 2018

Oncolytics Biotech(R) Announces Management Change

April 10, 2018

Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018

Page 28 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.